Oorja Bio

Oorja Bio is a clinical-stage biopharmaceutical company developing therapies for cardiopulmonary and fibrotic diseases, with a focus on drugs that target underlying disease pathways to promote cellular repair and tissue remodeling. The company's lead candidate, ORJ-001, is a first-in-class peptide therapeutic designed to treat idiopathic pulmonary fibrosis by restoring function of alveolar epithelial cells.